Quick Answer
CORCEPT THERAPEUTICS INC reported Total Revenue of $761.41 million for the year ending 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +12.8% in Total Revenue from 2024 to 2025.
- This data is from CORCEPT THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $27.60 million | Q2 2017: $35.56 million | Q3 2017: $42.76 million | Q4 2017: $53.28 million | Q1 2018: $57.66 million | Q2 2018: $62.31 million | Q3 2018: $64.45 million | Q4 2018: $66.83 million | Q1 2019: $64.83 million | Q2 2019: $72.26 million | Q3 2019: $81.51 million | Q4 2019: $87.90 million | Q1 2020: $93.25 million | Q2 2020: $88.57 million | Q3 2020: $86.33 million | Q4 2020: $85.74 million | Q1 2021: $79.44 million | Q2 2021: $91.59 million | Q3 2021: $96.13 million | Q1 2022: $93.69 million | Q2 2022: $103.39 million | Q3 2022: $101.73 million | Q1 2023: $105.65 million | Q2 2023: $117.72 million | Q3 2023: $123.60 million | Q1 2024: $146.81 million | Q2 2024: $163.80 million | Q3 2024: $182.55 million | Q1 2025: $157.21 million | Q2 2025: $194.43 million | Q3 2025: $207.64 million.
- Over the full 10 years of available data (2016 to 2025), CORCEPT THERAPEUTICS INC's Total Revenue has grown by 836.3%.
- Historical annual values: Fiscal year 2025: $761.41 million | Fiscal year 2024: $675.04 million | Fiscal year 2023: $482.38 million | Fiscal year 2022: $401.86 million | Fiscal year 2021: $365.98 million | Fiscal year 2020: $353.87 million | Fiscal year 2019: $306.49 million | Fiscal year 2018: $251.25 million | Fiscal year 2017: $159.20 million | Fiscal year 2016: $81.32 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: